Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice

Japanese Journal of Cancer Research

Volumn 88, Issue 8, 1997, Pages 760-769

  Takiguchi, Soichi ^a   Kumazawa, Eiji ^b   Shimazoe, Takao ^a   Tohgo, Akiko ^b   Kono, Akira ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Camptothecin; Drug resistance; DX 8951f; Nude mice; Pancreatic cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DNA FRAGMENT; DNA TOPOISOMERASE; IRINOTECAN; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CROSS RESISTANCE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0030805173     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00448.x     Document Type: Article

References (41)

1. Wall, M. E., Wani, M. C., Cook, C. E., Palmar, K. H., McPhail, A. T. and Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3890 (1966).
2. Gallo, R. C., Whang-Peng, J. and Adamson, R. H. Studies on the antitumor activity, mechanisms of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst., 46, 789-795 (1971).
3. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H. and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880), correlation with preclinical studies. Cancer Chemother. Rep., 56, 515-521 (1972).
4. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947 (1987).
5. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T. and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28, 192-198 (1981).
6. Takeda, S. and Kono, A. Inhibitory effects of CPT-11 on liver metastases in nude mice injected with human pancreatic tumor cells into their spleens. Jpn. J. Cancer Chemother., 17, 2433-2436 (1990), in Japanese.
7. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S. and Ota, K. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8, 1907-1912 (1990).
8. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K. and Takada, M. CPT-1, a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10, 1225-1229 (1992).
9. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10, 16-20 (1992).
10. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T. and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11, 909-913 (1993).
11. Futatsuki, K., Wakui, A., Nakao, I., Sakata, Y., Kambe, M., Shimada, Y., Yoshino, M., Taguchi, T. and Ogawa, N. Late phase II study of Irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn. J. Cancer Chemother., 21, 1033-1038 (1994), in Japanese.
12. Takeuchi, S., Takamizawa, H., Takeda, Y., Okawa, T., Tamaya, T., Noda, K., Sugawa, T., Sekiba, K., Yakushiji, M. and Taguchi, T. Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy. Proc. Am. Soc. Clin. Oncol., 10, 189 (1991).
13. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. and Sato, K. Intracellular role of SN-38, a metabolite of camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51, 4187-4190 (1991).
14. Hsiang, Y. R., Hertzberg, S., Hecht, S. and Leu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260, 14873-14878 (1985).
15. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs, a cautionary note. Cancer Res., 49, 5870-5878 (1989).
16. Tanizawa, A., Fujimori, A., Fujimori, Y. and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86, 836-842 (1994).
17. Huang, R. W., Takatsuki, K. and Tsuda, H. A new derivative of camptothecin, irinotecan hydrochloride (CPT-11) induces programmed cell death in leukemia/ lymphoma cell lines. Int. J. Oncol., 3, 679-685 (1993).
18. Kondo, S., Yin, D., Morimura, T. and Takeuchi, J. bcl-2 gene prevents induction of apoptosis in L1210 murine leukemia cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Int. J. Oncol., 4, 649-654 (1994).
19. Terasawa, H., Ohsuki, S. and Uoto, K. Hexa-cyclic compound. European Patent 0495432A1 (1992).
20. Mitsui, I., Kumazawa, E., Hirota, Y., Aonuma, M., Sugimori, M., Ohsuki, S., Uoto, K., Ejima, A., Terasawa, H. and Sato, K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res., 86, 776-782 (1995).
21. Wagener, D. J. T., Verdonk, H. E. R., Dirix, L. Y., Catimel, G., Siegenthaler, P., Buitenhuis, M., Mathier-Boue, A. and Verweij, J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol., 6, 129-132 (1995).
22. Sakata, Y., Shimada, Y., Yoshino, M., Kambe, M., Futatsuki, K., Nakao, I., Ogawa, N., Wakui, A. and Taguchi, T. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn. J. Cancer Chemother., 21, 1039-1046 (1994), in Japanese.
23. Iwamura, T., Katsuki, T. and Ide, K. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn. J. Cancer Res. (Gann), 78, 54-62 (1987).
24. Ikeda, Y., Ezaki, M., Hayashi, I., Yasuda, D., Nakayama, K. and Kono, A. Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice. Jpn. J. Cancer Res., 81, 987-993 (1990).
25. Takeda, S., Shimazoe, T., Sato, K., Sugimoto, Y., Tsuruo, T. and Kono, A. Differential expression of DNA topoisomerase I gene between CPT-11 acquired-and native-resistant human pancreatic tumor cell lines, detected by RNA/PCR-based quantitation assay. Biochem. Biophys. Res. Commun., 184, 618-625 (1992).
26. Kozlowski, J. M., Fidler, I. J., Campbell, D., Xu, Z., Edward Kaighn, M. and Hart, I. R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res., 44, 3522-3529 (1984).
27. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K. and Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl) camptothecin analogues, inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34, 98-107 (1991).
28. Mosmann, T. Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
29. Boliver, F., Rodriguez, R. L., Greene, P. J., Betlach, M. C., Heynecker, H. L., Boyer, H. W., Crosa, J. H. and Falkow, S. Construction and characterization of new cloning vehicles. Gene, 2, 95-113 (1977).
30. Liu, L. F. and Miller, K. G. Eukaryotic DNA topoisomerases, two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78, 3487-3491 (1981).
31. Smith, C. A., Williams, G. T., Kingston, R., Jenkinson, E. J. and Owen, J. T. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature, 337, 181-184 (1989).
32. Fujita, F., Fujita, M., Taguchi, T., Shimozuma, K., Sakamoto, Y., Kimoto, Y. and Hirai, T. Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int. J. Cancer, 43, 637-644 (1989).
33. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T. and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
34. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nagakawa, K., Fujisawa, Y., Liu, L. F. and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer, characterization and mechanism of resistance. Cancer Res., 50, 5919-5924 (1990).
35. Nagai, S., Yamauchi, M., Andoh, T., Nishizawa, M., Satta, T., Kodera, Y., Kondou, K., Akiyama, S., Ito, K. and Takagi, H. Establishment and characterization of human gastric and colonie xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol., 59, 116-124 (1995).
36. Kubota, N., Ohta, S., Takeda, Y., Ohmori, T., Nishio, K., Morikage, T., Fujiwara, Y., Kanzawa, F. and Saijo, N. Detection of topoisomerase I gene mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188, 571-577 (1992).
37. Aogi, K., Nishiyama, M., Hirabayashi, N., Toge, T., Okada, K., Kusano, T. and Ando, T. Establishment of a new multidrug-resistant cell line induced by continuous exposure to CPT-11. Proc. Am. Assoc. Cancer Res., 35, 451 (1994).
38. Ogasawara, H., Nishio, K., Kanzawa, F., Lee, Y.-S., Funayama, Y., Ohira, T., Kuraishi, Y., Isogai, Y. and Saijo, N. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Cancer Res., 86, 124-129 (1995).
39. Mitsui, I., Ohsuki, S., Hirota, Y., Sugimori, M., Terasawa, H. and Sato, K. High potency of a camptothecin derivative DX-8951 might be attributed to good membrane permeability. Proc. Am. Assoc. Cancer Res., 35, 455 (1994).
40. Tanizawa, A., Kohn, K. W., Kohlhagen, G., Leteurtre, F. and Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34, 7200-7206 (1995).
41. Ohmori, T., Podack, E. R., Nishio, K., Takahashi, M., Miyahara, Y., Takeda, Y., Kubota, N., Funayama, Y., Ogasawara, H., Ohira, T., Ohta, S. and Saijo, N. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-1, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun., 192, 30-36 (1993).